Migraine. Migraine without aura
Conditions
Interventions
Intervention 1: Intervention group: Eligible patients receive regular migraine treatment with a 500 mg tablet of Iaraj Fiqra (NIAK Pharmaceutical Company) for two months. Common medications include tr
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Having migraine without aura (according to the criteria of the International Headache Association (HIS), which is diagnosed by the physician Age between 18 and 65 History of migraine of at least one year The first migraine attack at the age of less than fifty years Have at least three attacks per month in the last three months Having a score higher than 6 according to the MIDAS questionnaire
Exclusion criteria
Exclusion criteria: Having headaches between two migraine attacks that are indistinguishable from migraine attacks Chronic tension headache or other types of headache for more than 15 days a month Pregnancy and lactation The presence of underlying heart problems such as arrhythmias History of biliary problems Comorbidities with inflammatory bowel diseases such as ulcerative colitis and Crohn's disease History of hemorrhoids Concomitant use of sedatives such as phenobarbital Concomitant use of diuretics, oral corticosteroids Concomitant use of laxatives such as polyethylene glycol or magnesium hydroxide Daily consumption of migraine prophylaxis for the past month Take at least three migraine medications for prophylaxis over the past ten years Drug or alcohol abuse Patient dissatisfaction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the number of migraine attacks. Timepoint: Upon arrival, first and second month. Method of measurement: MIDAS questionnaire (migraine disability assessment) and HIT-6 questionnaire (headache impact test -6).;Evaluation of the severity of migraine attacks. Timepoint: Upon arrival, first and second month. Method of measurement: MIDAS questionnaire (migraine disability assessment) and HIT-6 questionnaire (headache impact test -6).;Evaluation of the duration of migraine attacks. Timepoint: Upon arrival, first and second month. Method of measurement: MIDAS questionnaire (migraine disability assessment) and HIT-6 questionnaire (headache impact test -6). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSarah Mousavi
Esfahan University of Medical Sciences
Outcome results
None listed